Skip to main content
. 2022 Mar 14;28(6):1136–1146. doi: 10.1158/1078-0432.CCR-21-3213

Figure 3.

Figure 3. Ki-67, PD-1, and CTLA-4 expression by CD8+ and CD4+ T cells in TILs in MSS LARC group and TMB in both the MSS LARC and MSI-H LARC groups. A, Ki-67, PD-1, and CTLA-4 expression by CD8+ T cells in tumor infiltrating lymphocytes (TILs) in patients who achieved tumor regression grade (TRG) 0–1 and in patients who achieved TRG 2–3 at pre-CRT are shown. The differences between the two groups of patients were compared using a Mann-Whitney U test. B, PD-1 expression by both CD8+ T cells and effector memory cells (TEM) in TILs in patients who achieved TRG 0–1 and in patients who achieved TRG 2–3 at both the pre-CRT and post-CRT time are shown. The differences between the two groups of patients were compared using a Mann-Whitney U test. Because PD-1 expression could not be correctly evaluated during nivolumab therapy due to crossing with the PD-1 antibody, the data obtained after nivolumab therapy are not shown. C, CTLA-4 expression by both CD8+ T cells and the TEM subset in TILs in patients who achieved TRG 0–1 and in patients who achieved TRG 2–3 at four time points (pre-CRT, post-CRT, post-3 cycles of nivolumab, and post-5 cycles of nivolumab) are shown. The differences between the two groups of patients were compared using a Mann-Whitney U test. D, CTLA-4 expression by both CD4+ T cells and the TEM subtype in TILs in patients who achieved TRG 0–1 and in patients who achieved TRG 2–3 at four time points (pre-CRT, post-CRT, post-3 cycles of nivolumab, and post-5 cycles of nivolumab) are shown. The differences between the two groups of patients were compared using a Mann-Whitney U test. E, The tumor mutational burden (TMB) in pre-CRT samples in patients with microsatellite instability-high (MSI-H) locally advanced rectal cancer and in patients with microsatellite stable (MSS) LARC is shown (median 13.2/Mbp vs. median 0.99/Mbp). The differences between the two groups of patients were compared using a Mann-Whitney U test. F, The TMB in pre-CRT samples in patients with MSS LARC who achieved TRG 0–1 (median 1.45 mutations/Mbp) and in patients who achieved TRG 2–3 (median 0.84 mutations/Mbp) is shown. The differences between the two groups of patients were compared using a Mann-Whitney U test. TEM, effector memory (CCR7−CD45RA−).

Ki-67, PD-1, and CTLA-4 expression by CD8+ and CD4+ T cells in TILs in MSS LARC group and TMB in both the MSS LARC and MSI-H LARC groups. A, Ki-67, PD-1, and CTLA-4 expression by CD8+ T cells in tumor infiltrating lymphocytes (TILs) in patients who achieved tumor regression grade (TRG) 0–1 and in patients who achieved TRG 2–3 at pre-CRT are shown. The differences between the two groups of patients were compared using a Mann-Whitney U test. B, PD-1 expression by both CD8+ T cells and effector memory cells (TEM) in TILs in patients who achieved TRG 0–1 and in patients who achieved TRG 2–3 at both the pre-CRT and post-CRT time are shown. The differences between the two groups of patients were compared using a Mann-Whitney U test. Because PD-1 expression could not be correctly evaluated during nivolumab therapy due to crossing with the PD-1 antibody, the data obtained after nivolumab therapy are not shown. C, CTLA-4 expression by both CD8+ T cells and the TEM subset in TILs in patients who achieved TRG 0–1 and in patients who achieved TRG 2–3 at four time points (pre-CRT, post-CRT, post-3 cycles of nivolumab, and post-5 cycles of nivolumab) are shown. The differences between the two groups of patients were compared using a Mann-Whitney U test. D, CTLA-4 expression by both CD4+ T cells and the TEM subtype in TILs in patients who achieved TRG 0–1 and in patients who achieved TRG 2–3 at four time points (pre-CRT, post-CRT, post-3 cycles of nivolumab, and post-5 cycles of nivolumab) are shown. The differences between the two groups of patients were compared using a Mann-Whitney U test. E, The tumor mutational burden (TMB) in pre-CRT samples in patients with microsatellite instability-high (MSI-H) locally advanced rectal cancer and in patients with microsatellite stable (MSS) LARC is shown (median 13.2/Mbp vs. median 0.99/Mbp). The differences between the two groups of patients were compared using a Mann-Whitney U test. F, The TMB in pre-CRT samples in patients with MSS LARC who achieved TRG 0–1 (median 1.45 mutations/Mbp) and in patients who achieved TRG 2–3 (median 0.84 mutations/Mbp) is shown. The differences between the two groups of patients were compared using a Mann-Whitney U test. TEM, effector memory (CCR7−CD45RA−).